Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma

Published Date: 11 Oct 2024

Two-year survival in second line for patients with BRAF/NRAS wild-type tumors

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Relationship-building key to addressing oncologist shortages in rural care

2.

New protein target discovered for childhood medulloblastomas

3.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

4.

Papillary thyroid cancer: New markers offer hope for tailored treatment

5.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot